National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Vandetanib (Caprelsa®)

Vandetanib (Caprelsa®) for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.

Rapid Review

Commenced Completed Outcome
06/06/2013 03/07/2013 Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.